Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies
Open accessThe DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
The cardiovascular system ensures the delivery of oxygen and nutrients to all cells, tissues, and organs. Under extended exposure to reduced oxygen levels, cells are able to survive through the transcriptional activation of a series of genes that participate in angiogenesis, glucose metabolism, and cell proliferation. The oxygen-sensitive transcriptional activator HIF-1 (hypoxia-inducible factor-1) is a key transcriptional mediator of the response to hypoxic conditions. The HIF-1 pathway was found to be a master regulator of angiogenesis. Whether the process is physiological or pathological, HIF-1 seems to participate in vasculature formation by synergistic correlations with other proangiogenic factors such as VEGF (vascular endothelial growth factor), PlGF (placental growth factor), or angiopoietins. Considering the important contributions of HIF-1 in angiogenesis and vasculogenesis, it should be considered a promising target for treating ischaemic diseases or cancer. In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic representation of HIF-α gene structures and DNA binding. (a) HIF-1α and HIF-2α contain the following domains: a nuclear localisation domain (NLS), DNA binding and dimerisation domains (bHLH/PAS), oxygen-dependent degradation domain (ODDD), and cofactor interaction and transcriptional activity domains (N-TAD/C-TAD). HIF-3α lacks a C-TAD domain. NLS: nuclear localisation signal; bHLH: basic helix-loop-helix domain; PAS: Per-ARNT-Sim motif; ODDD: oxygen-dependent degradation domain; N-TAD: N-terminal transactivation domain; C-TAD: C-terminal transactivation domain. (b) Dimerisation of HIF-1α with HIF-1β under hypoxic conditions results in the formation of the HIF-1 transcription factor, which binds to hypoxia response elements (HREs) and activates the transcription of O2-dependent genes (according to [134]).](https://figures.cochat.ai/paper-figures/7f1eff6f4e4b425f9d8561e5e5c9be64/hypoxia-inducible-factor-1-in-physiological-and-pathophysiological-angiogenesis-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the normal developmental setting, HIF-1α plays a dominant role throughout vasculogenesis, whereas HIF-2α contributes primarily to vessel remodeling and maturation during the later stages of vasculogenesis (the HIF switch) [25].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Characteristics of tumor vasculature include lack of stabilization by pericytes and smooth muscle cells and a lack of an arterial or venous phenotype that leads to leakage, poor blood flow and perfusion (Figure 3) [25].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727 · cited 2×
“Because the uterine environment is hypoxic it is thereby obvious that hypoxiamay be the primary stimulus of vessel formation [3, 4].”
BackgroundMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276 · cited 1×
“growth factors that activate their receptors [5, 6].”
Mechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162 · cited 1×
“Vessel formation occurs via only two basicmechanisms: vasculogenesis and angiogenesis [2].”
BackgroundActivation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Research works printed but not linked: 11
- 1998, Journal of Cellular Biochemistry, 30-31, 168
- 2005, Science's STKE, 2005
- 1998, Gene Expression, 7, 205
- 1999, Cancer Research, 59, 3915
- 2003, Cancer Research, 63, 1138
- 1992, Obstetrics and Gynecology, 80, 283
- 2015, Tissue Engineering Part A, 21
- 1997, Tumour angiogenesis, 181
- 1998, Cancer Research, 58, 1408
- 2014, Journal of Physiology and Pharmacology, 65, 193
- 2000, Nature Medicine, 61, 49
Cited by
Items 101–200 of 650
Natural products targeting tumour angiogenesis
Lu, X., Friedrich, L. J., & Efferth, T. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16232 · Cited by 56
“…leading to an imbalance of pro-angiogenic and anti-angiogenic factors and further turning on the ‘ angiogenic switch ’ , where new vasculature is formed in and around the tumour, allowing it to grow exponentially (Carmeliet, 2005; Li, Song, et al., 2021; Zimna & Kurpisz, 2015) (see Figure 1).”
Luo, J., Sun, P., Zhang, X., Lin, G., Xin, Q., Niu, Y., Chen, Y., Xu, N., Zhang, Y., & Xie, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413336 · Cited by 56
“Since hypoxia is a key signal for the induction of tumor angiogenesis [22], we determined whether CANA could decrease angiogenesis under hypoxic conditions.”
Exosomes in Cardiovascular Disease: From Mechanism to Therapeutic Target
Reiss, A. B., Ahmed, S., Johnson, M., Saeedullah, U., & Leon, J. D. (2023) · Metabolites · doi:10.3390/metabo13040479 · Cited by 56
“Primary neonatal cardiomyocytes [94,95] Anti-angiogenic MiR-19a-3p”
BackgroundSrivastava, A., Yadav, T. C., Khera, H. K., Mishra, P., Raghuwanshi, N., Pruthi, V., & Prasad, R. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102614 · Cited by 57
Jin, F., Zheng, X., Yang, Y., Yao, G., Ye, L., Doeppner, T. R., Hermann, D. M., Wang, H., & Dai, Y. (2019) · Aging · doi:10.18632/aging.101726 · Cited by 50
“The transcription factor HIFs are central regulators of adaptive responses to hypoxia in various physiological and pathological processes, including angiogenesis and inflammation [41].”
BackgroundMelatonin is a potential inhibitor of ovarian cancer: molecular aspects
Zare, H., Shafabakhsh, R., Reiter, R. J., & Asemi, Z. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0502-8 · Cited by 59
Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy
Li, S., Zhang, Q., & Hong, Y. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820980116 · Cited by 53
“It participates in vasculature formation with other proangiogenic factors, such as VEGF and angiopoietin.(70) Apart from its proangiogenic effects, HIF-1 also reprograms immune cells into a protumor phenotype.”
BackgroundTan, Z. W., Zhou, B., Zheng, J., Huang, Y., Zeng, H., Xue, L., & Wang, D. (2021) · Stem Cells International · doi:10.1155/2021/6662164 · Cited by 52
RetractedLi, X., Chen, C., Dai, Y., Huang, C., Han, Q., Jing, L., Ma, Y., Xu, Y., Liu, Y., Zhao, L., et al. (2019) · Cancer Science · doi:10.1111/cas.13988 · Cited by 51
The circadian protein BMAL1 supports endothelial cell cycle during angiogenesis
Astone, M., Oberkersch, R. E., Tosi, G., Biscontin, A., & Santoro, M. M. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad057 · Cited by 51
The impact of HPV infection on human glycogen and lipid metabolism – a review
Sitarz, K., Czamara, K., Szostek, S., & Kaczor, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188646 · Cited by 53
Raeiszadeh, M., Tarzi, M. E., Juybari, K. B., Nematollahi‐Mahani, S. N., Pardakhty, A., Nematollahi, M. H., Mehrabani, M., & Mehrabani, M. (2018) · South African Journal of Botany · doi:10.1016/j.sajb.2018.07.006 · Cited by 54
Song, W., Puttabyatappa, M., Zeng, L., Vázquez, D. M., Pennathur, S., & Padmanabhan, V. (2019) · Chemosphere · doi:10.1016/j.chemosphere.2019.125301 · Cited by 49
“the VEGF disruption may be manifest during later stage of gestation, since HIF1A is known to exert its proangiogenic role by increasing VEGF expression (Zimna and Kurpisz, 2015).”
BackgroundTAK1 signaling is a potential therapeutic target for pathological angiogenesis
Zhu, L., Lama, S., Tu, L., Dusting, G. J., Wang, J.-H., & Liu, G. (2021) · Angiogenesis · doi:10.1007/s10456-021-09787-5 · Cited by 50
“Studies have shown that hypoxia and ischemia in the retina contribute to the progression of retinal neovascularization through HIF-1α- and NF-κB-related signaling involving TAK1 signaling [80].”
BackgroundA Functional CT Contrast Agent for In Vivo Imaging of Tumor Hypoxia
Shi, H., Wang, Z., Huang, C., Gu, X., Jia, T., Zhang, A., Wu, Z., Zhu, L., Luo, X., Zhao, X., et al. (2016) · Small · doi:10.1002/smll.201601029 · Cited by 50
Shi, L., Zhang, G., Zheng, Z., Lü, B., & Ji, L. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.06.024 · Cited by 48
Cellular and Molecular Heterogeneity Associated with Vessel Formation Processes
Castro, P. R., Barbosa, A. S., Pereira, J. M., Ranfley, H., Felipetto, M., Gonçalves, C. A. X., Paiva, I. R., Berg, B. B., & Barcelos, L. S. (2018) · BioMed Research International · doi:10.1155/2018/6740408 · Cited by 47
“In general, the factors involved in the angiogenic process are VEGF and hypoxia-inducible factor 1 (HIF-1), the main agents that orchestrate vascular homeostasis and promote an increment on vascular permeability, migration, and proliferation of EC [88, 93]; angiopoietin-1 and angiopoietin- 2 (Ang-1 and Ang2), which ex…”
BackgroundRecurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects
Pineda, E., Doménech, M., Hernández, A., Comas, S., & Balañá, C. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s366371 · Cited by 48
Transcription factors regulating vasculogenesis and angiogenesis
Payne, S., Neal, A., & Val, S. D. (2023) · Developmental Dynamics · doi:10.1002/dvdy.575 · Cited by 46
“212,213 While Hif1a is ubiquitously expressed, Hif1b is predominantly EC-specific from E8.”
BackgroundShaji, M., Tamada, A., Fujimoto, K., Muguruma, K., Karsten, S. L., & Yokokawa, R. (2024) · Lab on a Chip · doi:10.1039/d3lc00930k · Cited by 45
Shaabani, E., Sharifiaghdam, M., Lammens, J., Keersmaecker, H. D., Vervaet, C., Beer, T. D., Motevaseli, E., Ghahremani, M. H., Mansouri, P., Smedt, S. C. D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179216 · Cited by 46
“At the molecular level, the angiogenic process is regulated by hypoxia-inducible factor-1 (HIF-1) [28,29], which mediates the cellular response to hypoxia, and promotes pro-angiogenic gene transcription, thus stimulating neovascularization [30,31].”
BackgroundZhou, Y., Yang, C., Wang, K., Liu, X., & Liu, Q. (2016) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14743337535446 · Cited by 43
RetractedZhang, J., Shen, Y., Liu, C., Yang, J., Yang, Y., Zhang, C., Bian, S., Yu, J., Gao, X., Zhang, L.-P., et al. (2020) · Military Medical Research · doi:10.1186/s40779-020-00264-6 · Cited by 44
“HIFs are transcription factors that directly or indirectly regulate hundreds of genes involved in angiogenesis, cell growth, apoptosis, energy metabolism and vasomotor regulation [11, 12].”
BackgroundAntiangiogenic Activity of Flavonoids: A Systematic Review and Meta-Analysis
Khater, M. A., Greco, F., & Osborn, H. M. I. (2020) · Molecules · doi:10.3390/molecules25204712 · Cited by 43
“The HIFs are major regulators of angiogenesis and orchestrate many of the steps involved [182].”
BackgroundTsiapalis, D., Pieri, A. D., Spanoudes, K., Sallent, I., Kearns, S. R., Kelly, J. L., Raghunath, M., & Zeugolis, D. I. (2019) · Biofabrication · doi:10.1088/1758-5090/ab6412 · Cited by 43
Cuproptosis: emerging biomarkers and potential therapeutics in cancers
Wang, M., Zheng, L., Ma, S., Lin, R., Li, J., & Yang, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1288504 · Cited by 44
Extracellular vesicles in cancers: mechanisms, biomarkers, and therapeutic strategies
Ma, Y., Zhang, X., Liu, C., & Zhao, Y. (2024) · MedComm · doi:10.1002/mco2.70009 · Cited by 45
Hahne, M., Schumann, P., Mursell, M., Strehl, C., Hoff, P., Buttgereit, F., & Gaber, T. (2017) · Microvascular Research · doi:10.1016/j.mvr.2017.09.004 · Cited by 41
“A key regulator of hypoxia induced cellular adaption processes – including angiogenesis and metabolic reprogramming – is a transcription factor called hypoxia-inducible factor (HIF) (Gaber et al., 2005; Krock et al., 2011; Zimna and Kurpisz, 2015).”
BackgroundInfluentialPardue, S., Kolluru, G. K., Shen, X., Lewis, S. E., Saffle, C. B., Kelley, E. E., & Kevil, C. G. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101447 · Cited by 42
“XOR is transcribed from a single gene Xdh, which serves to oxidize hypoxanthine to xanthine, and xanthine to UA while reducing NAD+ to NADH.”
BackgroundMicroRNA-regulated pathways of flow-stimulated angiogenesis and vascular remodeling in vivo
Henn, D., Abu‐Halima, M., Wermke, D., Falkner, F., Thomas, B., Koepple, C., Ludwig, N., Schulte, M., Brockmann, M. A., Kim, Y., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1767-9 · Cited by 40
Nazari‐Shafti, T. Z., Neuber, S., Duran, A. G., Xu, Z.-Y., Beltsios, E. T., Seifert, M., Falk, V., & Stamm, C. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0432 · Cited by 41
Biological and Clinical Aspects of Metastatic Spinal Tumors
Litak, J., Czyżewski, W., Szymoniuk, M., Sakwa, L., Pasierb, B., Litak, J., Hoffman, Z., Kamieniak, P., & Roliński, J. (2022) · Cancers · doi:10.3390/cancers14194599 · Cited by 43
Abdel-Hamed, A. R., Mehanna, E. T., Hazem, R. M., Badr, J. M., Abo–Elmatty, D. M., Abdel-Kader, M. S., & Goda, M. S. (2021) · Antioxidants · doi:10.3390/antiox10111701 · Cited by 41
Stepanov, Y. V., Golovynska, I., Golovynskyi, S., Garmanchuk, L., Gorbach, O. I., Stepanova, L. I., Khranovska, N., Остапченко, Л. І., Ohulchanskyy, T. Y., & Qu, J. (2022) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2022.112388 · Cited by 43
Therapeutic Effects of Natural Products on Cervical Cancer: Based on Inflammatory Pathways
Zhou, Z., Long, H., Xu, S., Li, F., Cheng, Y., Luo, H., & Gao, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.899208 · Cited by 43
Koh, Y. W., Lee, S. J., Han, J., Haam, S., Jung, J., & Lee, H. W. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.004 · Cited by 38
Succinate as a signaling molecule in the mediation of liver diseases
Chen, H., Jin, C., Xie, L. H., & Wu, J. H. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166935 · Cited by 38
Yüce, H. B., Karataş, Ő., Tulu, F., Altan, A., & Gevrek, F. (2018) · Biotechnic & Histochemistry · doi:10.1080/10520295.2018.1508745 · Cited by 39
“The pathogenic processes of both diabetes and periodontitis require a series of events and biological signal molecules, such as up-regulation of HIF-1α, interleukins and other cytokines, and of VEGF (Polverini 1995; Chung et al. 2010; Claudino et al. 2012; Wu et al. 2013; Zimna and Kurpisz 2015).”
BackgroundTumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy
Kang, X., Huang, Y., Wang, H., Jadhav, S., Yue, Z., Tiwari, A. K., & Babu, R. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010061 · Cited by 38
“Additionally, TAMs impair dendritic cell (DC) function via IL-6, nitric-oxide synthase 2 (NOS2), cyclooxygenase-2 (COX2) [41,42], VEGF [43–45], prostaglandin E2 (PGE2) [46,47], and TGF-β [48,49].”
BackgroundInfluentialJain, S. M., Ravichandran, S. N., Kumar, M. M., Banerjee, A., Sun-Zhang, A., Zhang, H., Pathak, R., Sun, X., & Pathak, S. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2317999 · Cited by 36
“11 By altering Notch signaling, hypoxia can regulate vascular branching.”
BackgroundMitaishvili, E., Feinsod, H., David, Z., Shpigel, J., Fernandez, C., Sauane, M., & de la Parra, C. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2903099 · Cited by 37
“In hypoxic tumor environments, the activation HIF-1 α triggers increased VEGF expression, stimulating the formation of new blood vessels [23,24].”
BackgroundAngiogenesis and EMT regulators in the tumor microenvironment in lung cancer and immunotherapy
Yan, T., & Shi, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1509195 · Cited by 40
Ezcurra, A. L. D. L., Bertolin, A. P., Kim, K., Katz, M. J., Gándara, L., Misra, T., Luschnig, S., Perrimon, N., Melani, M., & Wappner, P. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006073 · Cited by 39
“Hypoxic microenvironment is a common feature of many solid tumors [82,83], and most primary human cancers and their metastases exhibit increased levels of HIFα [84].”
BackgroundPisani, F., Cammalleri, M., Monte, M. D., Locri, F., Mola, M. G., Nicchia, G. P., Frigeri, A., Bagnoli, P., & Svelto, M. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13348 · Cited by 38
“There is also evidence of functional interactions between AQP4 and hypoxia-inducible factor-1 (HIF-1), the major transcription factor regulating VEGF levels in response to hypoxia [19].”
Loizzi, V., Ranieri, G., Laforgia, M., Gadaleta, C. D., Gargano, G., Kardhashi, A., Liso, M. D., Naglieri, E., Vecchio, V. D., Cicinelli, E., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11951 · Cited by 36
Marconi, G. D., Rocca, Y. D., Fonticoli, L., Melfi, F., Rajan, T. S., Carradori, S., Pizzicannella, J., Trubiani, O., & Diomede, F. (2022) · Pharmaceuticals · doi:10.3390/ph15070890 · Cited by 36
“Based on the literature, oncogenic c-Myc cooperates with HIF-1α to trigger VEGF production and release [29,30].”
BackgroundTherapeutic Angiogenesis: Angiogenic Growth Factors for Ischemic Heart Disease
Henning, R. J. (2016) · Future Cardiology · doi:10.2217/fca-2016-0006 · Cited by 37
Schwartzman, J. D., McCall, M., Ghattas, Y. S., Pugazhendhi, A. S., Wei, F., Ngo, C., Ruiz, J., Seal, S., & Coathup, M. J. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122683 · Cited by 36
Metastasis inhibition in breast cancer by targeting cancer cell extravasation
Cominetti, M. R., Altei, W. F., & Selistre-de-Araújo, H. S. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s166725 · Cited by 38
“17,18 The angiogenic switch, supported by a set of distinct cell types and molecules present in the tumor microenvironment, modulates the transition from a quiescent to a proliferative vasculature.”
miR-18a Inhibits BMP4 and HIF-1α Normalizing Brain Arteriovenous Malformations
Marín‐Ramos, N. I., Thein, T. Z., Ghaghada, K. B., Chen, T. C., Giannotta, S. L., & Hofman, F. M. (2020) · Circulation Research · doi:10.1161/circresaha.119.316317 · Cited by 36
Wang, L., Wu, H., Xiong, L., Liu, X., Yang, N., Luo, L., Qin, T., Zhu, X., Shen, Z., Hua, J., et al. (2020) · BioMed Research International · doi:10.1155/2020/9485398 · Cited by 34
“VEGF is one of the most potent angiogenic factors, which is capable of promoting endothelial cell proliferation and migration and inducing vascular permeability [10].”
InfluentialLuo, N., Cheng, W., Zhou, Y., Gu, B., Zhao, Z., & Zhao, Y. (2021) · Animals · doi:10.3390/ani11072132 · Cited by 42
“In addition, HIF is an important component of vasculature formation by synergistic correlations with other proangiogenic factors, such as VEGF (vascular endothelial growth factor) and PlGF (placental growth factor) [65].”
BackgroundRole of NOD- like Receptors in Glioma Angiogenesis: Insights into future therapeutic interventions
Saxena, S., & Jha, S. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.02.001 · Cited by 35
“This hypoxic environment causes the induction of HIF-1a, which upregulates a broad array of angiogenic genes in response to oxygen deprivation like VEGF and epidermal growth factor (EGF) [62].”
BackgroundPortillo, A. L., Monteiro, J. K., Rojas, E. A. P., Ritchie, T. M., Gillgrass, A. E., & Ashkar, A. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1286750 · Cited by 35
“Hypoxia induces signalling of the major hypoxia inducible factor (HIF) pathway, which alters the balance in the production of pro-and anti-angiogenic factors promoting tumor angiogenesis (55).”
BackgroundCopper homeostasis dysregulation in respiratory diseases: a review of current knowledge
Song, W., Yue, Y., Zhang, Q., & Wang, X. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1243629 · Cited by 34
Li, J., Zhou, W., Chen, W., Wang, H., Zhang, Y., & Yu, T. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10966 · Cited by 34
“These factors are involved in a number of physiological responses, such as anaerobic metabolism, angiogenesis, erythrocyte production, cell proliferation and apoptosis (23,24).”
BackgroundMiao, A.-F., Liang, J.-X., Yao, L., Han, J.-L., & Zhou, L.-J. (2021) · Figshare · doi:10.6084/m9.figshare.14564335 · Cited by 33
Hypoxia-inducible factor-1: Regulatory mechanisms and drug therapy in myocardial infarction
Pan, J., Zhang, L., Li, D., Li, Y., Lu, M., Hu, Y., Sun, B., Zhang, Z., & Li, C. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176277 · Cited by 32
Mild anemia during pregnancy upregulates placental vascularity development
Stangret, A., Skoda, M., Wnuk, A., Pyźlak, M., & Szukiewicz, D. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.03.007 · Cited by 32
“or PlGF which activate their receptors [55-62].”
Bahadori, M. B., Vandghanooni, S., Dinparast, L., Eskandani, M., Ayatollahi, S. A., Ata, A., & Nazemiyeh, H. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.03.013 · Cited by 32
Controversies Regarding the Management of Teeth Associated with Cystic Lesions of the Jaws.
Zhao, Y. F., Bing, L., & Zhao, Y. F. (2019) · PubMed · doi:10.3290/j.cjdr.a42512 · Cited by 37
Al-Ostoot, F. H., Sherapura, A., Vellingiri, V., Basappa, G., Kameshwar, V. H., Thippegowda, P. B., & Khanum, S. A. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00266-8 · Cited by 32
“Many proangiogenic factors including VEGF are activated in response to signals leading to damage in blood vessels, infraction, and reduction in the flow of blood that lead to a decrease in the supply of oxygen [1].”
BackgroundIs Curcumin the Answer to Future Chemotherapy Cocktail?
Kong, W. Y., Ngai, S. C., Goh, B. H., Lee, L., Htar, T. T., & Chuah, L. (2021) · Molecules · doi:10.3390/molecules26144329 · Cited by 33
“Furthermore, in order to survive in an oxygen-deprived condition, cancer cells had augmented the expression of hypoxia-inducible factor 1-α (HIF-1α) which could, in turn, stimulate pro-angiogenic activities [34].”
BackgroundMore Than Meets the Eye Regarding Cancer Metabolism
Kubicka, A., Matczak, K., & Łabieniec-Watała, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179507 · Cited by 32
“During normoxia, HIF-1α is rapidly degraded, with the involvement of ubiquitin and with activation of the tumour suppressor protein pVHL [59].”
BackgroundPrognostic role of hypoxia-inducible factor-1 alpha expression in osteosarcoma: a meta-analysis
Ren, H., Li, H., Xie, T., Sun, L., Zhu, T., Wang, S. D., Ye, Z. M., & Zhang, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s95490 · Cited by 32
“The dimer binds to highly conserved hypoxia-response elements in the promoter of target genes and activates their expressions to mediate acute and chronic adaptation to oxygen deficiency, including erythropoiesis, glycolysis, angiogenesis, inhibition of apoptosis, inhibition of cell differentiation, and promotion of c…”
Xie, Q., Xie, J., Zhong, J., Cun, X., Lin, S., Lin, Y., & Cai, X. (2016) · Cell Proliferation · doi:10.1111/cpr.12244 · Cited by 35
Cancer-triggered systemic disease and therapeutic targets
Cao, Y. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00077-w · Cited by 33
“Hypoxia upregulates VEGF expression via the HIF-1α-triggered transcription activation of the VEGF gene promoter [70, 71]; and 4) Accumulation of metabolites.”
BackgroundFischer, A. P., & Miles, S. L. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.056 · Cited by 33
Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review
Saxena, R., Welsh, C. M., & He, Y.-W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1462339 · Cited by 33
Maternal High Linoleic Acid Alters Placental Fatty Acid Composition
Shrestha, N., Holland, O. J., Kent, N. L., Perkins, A. V., McAinch, A. J., Cuffe, J. S. M., & Hryciw, D. H. (2020) · Nutrients · doi:10.3390/nu12082183 · Cited by 30
“Angiogenic factors include the vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), angiopoietin (ANG) protein families, and hypoxia-inducible factor 1 (HIF-1), as well as their respective receptors [39,41].”
BackgroundVascular endothelial growth factor-mediated peritoneal neoangiogenesis in peritoneal dialysis
Shi, Y., Hu, Y., Cui, B., Zhuang, S., & Liu, N. (2021) · Peritoneal Dialysis International · doi:10.1177/08968608211004683 · Cited by 30
“Under hypoxic conditions, HIF-1 directly up-regulates VEGF level and induces initiation of vessel formation cascade.(55,56) Then, HIF-1 has the ability to mediate endothelial cell behavior and stimulate endothelial cell proliferation and adhesion by integrin ab.”
BackgroundRNA‐binding proteins and translation control in angiogenesis
Smith, M. R., & Costa, G. (2021) · FEBS Journal · doi:10.1111/febs.16286 · Cited by 30
Sadgrove, N. J., Batra, S., Barreto, D., & Rapaport, J. A. (2023) · Cosmetics · doi:10.3390/cosmetics10040106 · Cited by 32
Chen, H., Li, J., Liang, S., Lin, B., Peng, Q., Zhao, P., Cui, J., & Rao, Y. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4049 · Cited by 30
“It is an important transcriptional regulator of the cellular adaptation to hypoxia and is associated with a number of diseases (17).”
BackgroundEmerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma
Osinga, T. E., Links, T. P., Dullaart, R. P. F., Pacák, K., van der Horst‐Schrivers, A. N. A., Kerstens, M. N., & Kema, I. P. (2017) · The FASEB Journal · doi:10.1096/fj.201601131r · Cited by 32
Wei, Y., Wang, L., Zheng, J., Jia, Q., Brčić, L., Akaba, T., & Chu, Q. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-127 · Cited by 29
Liu, J., Huang, X., Su, H., Yu, J., Nie, X., Liu, K., Qin, W., Zhao, Y., Su, Y., Kuang, X., et al. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s456590 · Cited by 29
“58,59 Studies of longitudinal distraction osteogenesis detected elevated expression of HIF-1α in the distracted gap and in serum.”
BackgroundChen, C.-F., & Liao, H.-T. (2018) · World Journal of Stem Cells · doi:10.4252/wjsc.v10.i12.212 · Cited by 29
Yang, M. S., Zhu, M., Song, K., Wuren, T., Yan, J. X., Ge, R., Ji, L., & Cui, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118873 · Cited by 31
Wang, Q., Zhang, F., Yang, L., Liu, P., Liu, C., & Tao, Y. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118819 · Cited by 29
Detection of pro angiogenic and inflammatory biomarkers in patients with CKD
Jalal, D. I., Sanford, B. L., Renner, B., Eyck, P. T., Laskowski, J., Cooper, J., Sun, M., Zakharia, Y., Spitz, D. R., Dokun, A. O., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87710-0 · Cited by 29
Fang, C., Dai, L., Wang, C., Fan, C., Yu, Y., Yang, L., Deng, H., & Zhou, Z. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13044 · Cited by 31
“However, the location of SCG2 in the cytoplasm indicated that SCG2 may inhibit the transcription of VEGF by regulating the expression of transcription factors, such as HIF-1 [28-30].”
BackgroundLiu, X., Huang, K., Zhang, F., Huang, G., Wang, L., Wu, G., Ren, H., Yang, G., & Lin, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02614-1 · Cited by 30
“The study of other target genes has also provided more options for gene therapy of FNDs. Hif-1 α is a major regulator of cellular hypoxic responses [271] and transcriptionally activates a variety of pro-angiogenic factors, chemokines, and receptors, including VEGF, PDGF-B, and ANG1/2.”
BackgroundLiraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury
Chong, L., Liu, Y., He, J. N., Mu, R., Di, Y., Shen, N., Liu, X., Gao, X., Wang, J., Chen, T., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00789 · Cited by 30
Feng, J., Byrne, N. M., Al-Jamal, W. T., & Coulter, J. A. (2019) · Cancers · doi:10.3390/cancers11121989 · Cited by 29
“This typically includes the activation of angiogenic genes and receptors such as VEGF (vascular endothelial growth factor), PLGF (placental growth factor), PDGFB (platelet-derived factor) and integrins among others (Figure 2) [80].”
BackgroundRazavi, Z. S., Sharafshadehi, S. A., Yousefi, M. H., Tehrani, F. J., Barghani, M. R. R., Afkhami, H., & Heidari, F. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-024-03790-8 · Cited by 28
Zhao, X., Wei, X., Wang, X., & Qi, G. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11064 · Cited by 29
“Primers were purchased from GenScript and the sequences were: hsa-mir-590-3p/mmu-mir-590-3p forward, 5'-Taa TTT TaT GTa Taa GcT aGT-3'; hsa-mir-590-3p/mmu-mir-590-3p reverse, 5'-Gca GGG Tcc GaG GTa TTc-3'; 5S forward, 5'-GaT cTc GGa aGc Taa Gca GG-3'; 5S reverse, 5'-TGG TGc aGG GTc cGa GGT aT-3'; mmu-5S forward, 5'-cT…”
BackgroundInfluentialAn overview of biological research on hypoxia-inducible factors (HIFs)
Liu, Z., Wu, Z., Fan, Y., & Fang, Y. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2020.0064 · Cited by 30
“The compound CJ-3k designed and synthesised according to the structure of YC-1 can also effectively inhibit the activity of HIF-1a [98].”
BackgroundKimura, K., Jackson, T. L. B., & Huang, R. C. C. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110580 · Cited by 30
“…epidermal growth factor receptor (EGFR), and VEGF receptor 3 (VEGFR3) [65–67], whereas HIF-1 is a master regulator of angiogenesis, participating in vasculature formation by synergistic correlations with other proangiogenic factors such as VEGF, placental growth factor, and angiopoietins [68].”
Atlas on substrate recognition subunits of CRL2 E3 ligases
Wang, S., Xia, W., Qiu, M., Wang, X., Jiang, F., Yin, R. H., & Xu, L. (2016) · Oncotarget · doi:10.18632/oncotarget.8732 · Cited by 28
“Activation of HIF allows for enhanced angiogenesis, which in turn allows for increased glucose intake [46].”
BackgroundYu, T., Dong, C., Shen, Z., Chen, Y., Yu, B., Shi, H., Zhou, C., & Ye, J. (2016) · Materials Science and Engineering C · doi:10.1016/j.msec.2016.05.106 · Cited by 28
Kasture, V., Sundrani, D. P., Dalvi, S., Swamy, M., Kale, A. A., & Joshi, S. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03599-4 · Cited by 28
Hypoxia during incubation and its effects on broiler's embryonic development
Haron, A., Ruzal, M., Shinder, D., & Druyan, S. (2021) · Poultry Science · doi:10.1016/j.psj.2020.12.048 · Cited by 32
“The oxygenic balance can be disturbed by rapid cellular division during embryonic development, tumor growth, or vasculature dysfunction due to vessel occlusion or rupture (Zimna and Kurpisz, 2015).”
BackgroundHypoxia-inducible-factor-1 in trauma and critical care
Bogdanovski, D. A., DiFazio, L. T., Bogdanovski, A. K., Csóka, B., Jordan, G. B., Paul, E. R., Antonioli, L., Pilip, S. A., & Németh, Z. H. (2017) · Journal of Critical Care · doi:10.1016/j.jcrc.2017.07.029 · Cited by 31
Bloomer, R. J., Martin, K. R., & Pence, J. C. (2022) · Journal of Clinical and Translational Research · doi:10.18053/jctres.08.202202.005 · Cited by 27
“The secondary regulatory way acts by hydroxylation of asparagine residues by factor inhibiting HIF-1, preventing HIF-1a from interacting within co-activators such as CREB-binding protein and E1A binding protein p300 [28].”
BackgroundInfluentialSex and Racial Disparities in Peripheral Artery Disease
Divakaran, S., Krawisz, A. K., Secemsky, E. A., & Kant, S. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319399 · Cited by 27
“42,43 The subsequent signaling by VEGF directs endothelial cells to hypoxic regions, enabling their participation in the formation of new blood vessels.”
The pathogenesis and regulatory role of HIF-1 in rheumatoid arthritis
Li, H., Wu, Q.-Y., Teng, X.-H., Li, Z.-P., Zhu, M., Gu, C.-J., Chen, B.-J., Xie, Q.-Q., & Luo, X.-J. (2024) · Central European Journal of Immunology · doi:10.5114/ceji.2023.134217 · Cited by 31
“Furthermore, HIF-1 can stimulate angiogenesis by triggering the production of vascular endothelial growth factor (VEGF), which participates in angiogenesis and leads to many diseases [11].”
BackgroundChen, M., Hsu, W., Chang, W.-L., & Chou, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-05512-9 · Cited by 30
Umar, A. K., Limpikirati, P. K., Rivai, B., Ardiansah, I., Sriwidodo, S., & Luckanagul, J. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41246 · Cited by 26
“This includes stimulation of angiogenesis where HIF-1 triggers the production of blood vessel growth factors such as vascular endothelial growth factor (VEGF) to promote the formation of new blood vessels [239].”
Neurovascular abnormalities in retinopathy of prematurity and emerging therapies
Dai, C., Xiao, J., Wang, C., Li, W., & Su, G. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02195-2 · Cited by 26
“VEGF expression is regulated by HIF transcription factor family, of which HIF-1 and 2 are the most characterized [89, 90].”
Background
Metadata
- Authors
- Zimna, A., & Kurpisz, M.
- Affiliations
- Institute of Human Genetics (PL)
- Corresponding author
- Kurpisz, Maciej
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-13
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC4471260
- OpenAlex
- W1597158509
- Cited by
- 604
- References
- 138
- Citations by year
- 2026: 40 · 2025: 66 · 2024: 88 · 2023: 78 · 2022: 67 · 2021: 79 · 2020: 64 · 2019: 45 · 2018: 22 · 2017: 28 · 2016: 23 · 2015: 3
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Science Centre, Poland (2012/07/N/NZ3/01687, 2014/13/B/NZ3/04646, STRATEGMED1/233624/5/NCBR/2014)
- National Centre for Research and Development (2012/07/N/NZ3/01687, 2014/13/B/NZ3/04646, STRATEGMED1/233624/5/NCBR/2014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- HIF-1, angiogenesis, hypoxia, vascular endothelial growth factor, placental growth factor, angiopoietins, vasculogenesis, ischemic diseases, cancer, oxygen sensing, transcriptional regulation
- MeSH terms
- Placenta Growth Factor, Hypoxia, Humans, Neovascularization, Pathologic, Pregnancy Proteins, Transcriptional Activation, Cell Hypoxia, Neovascularization, Physiologic, Vascular Endothelial Growth Factor A, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.